Metabolic and toxic effects of mithramycin during tumor therapy.
D000230:Adenocarcinoma / Q000188:drug therapy; D000410:Alanine Transaminase / Q000097:blood; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism*; D001219:Aspartate Aminotransferases / Q000097:blood; D001772:Blood Cell Count; D001806:Blood Urea Nitrogen; D002118:Calcium / Q000097:blood; D055598:Chemical Phenomena; D002621:Chemistry; D005909:Glioblastoma / Q000188:drug therapy; D006474:Hemorrhagic Disorders / Q000139:chemically induced; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000188:drug therapy; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007964:Leukocytosis / Q000139:chemically induced; D007970:Leukopenia / Q000139:chemically induced; D008099:Liver / Q000187:drug effects; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D009954:Ornithine Carbamoyltransferase / Q000097:blood; D010758:Phosphorus / Q000097:blood; D013736:Testicular Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D010758:Phosphorus; D007770:L-Lactate Dehydrogenase; D009954:Ornithine Carbamoyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D002118:Calcium